• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

加拿大的戒烟药物使用、补贴政策与戒烟情况

Stop-Smoking Medication Use, Subsidization Policies, and Cessation in Canada.

作者信息

White Christine M, Rynard Vicki L, Reid Jessica L, Ahmed Rashid, Burkhalter Robin, Hammond David

机构信息

School of Public Health and Health Systems, University of Waterloo, Waterloo, Ontario, Canada.

Propel Centre for Population Health Impact, University of Waterloo, Waterloo, Ontario, Canada.

出版信息

Am J Prev Med. 2015 Aug;49(2):188-98. doi: 10.1016/j.amepre.2015.03.001. Epub 2015 May 29.

DOI:10.1016/j.amepre.2015.03.001
PMID:26033348
Abstract

INTRODUCTION

In 2000, Quebec began reimbursing stop-smoking medications (SSMs) through their provincial public drug insurance plan. Several other Canadian provinces have since begun offering SSM subsidies. Clinical trials indicate that SSMs can increase quit success; however, little evidence exists on patterns of use in "real-world" settings and impact on population quit rates. This study examines Canadian trends in SSM use and quit success over time, comparing provinces with differing subsidization policies.

METHODS

Secondary analyses were conducted in 2014 using nationally representative Canadian Tobacco Use Monitoring Survey data, 2004-2012, for current and former smokers who made a quit attempt in the past 2 years (N=26,094). Regression models tested for differences in SSM use and quit success in provinces with differing SSM coverage (i.e., none, partial, or comprehensive).

RESULTS

Smokers were more likely to use nicotine replacement therapy (NRT) in jurisdictions with comprehensive SSM coverage versus jurisdictions with partial (OR=1.39, 95% CI=1.22, 1.59) or no coverage (OR=1.43, 95% CI=1.21, 1.68). Prescription medication use was more likely in provinces with partial (versus no) coverage (OR=1.27, 95% CI=1.01, 1.59). Overall, smokers who attempted to quit were more likely to remain abstinent in jurisdictions with comprehensive versus partial (OR=1.20, 95% CI=1.12, 1.28) or no coverage (OR=1.23, 95% CI=1.00, 1.50). An interaction between coverage and cigarettes per day was observed, suggesting potentially greater impact of comprehensive coverage among heavier smokers.

CONCLUSIONS

Comprehensive subsidization policies are associated with modest increases in NRT use and quit success, but do not appear to impact prescription SSM use.

摘要

引言

2000年,魁北克省开始通过其省级公共药物保险计划报销戒烟药物(SSM)费用。此后,加拿大其他几个省份也开始提供SSM补贴。临床试验表明,SSM可提高戒烟成功率;然而,关于“现实世界”环境中的使用模式及其对总体戒烟率的影响,几乎没有证据。本研究考察了加拿大随时间推移的SSM使用趋势和戒烟成功率,并比较了具有不同补贴政策的省份。

方法

2014年,利用具有全国代表性的2004 - 2012年加拿大烟草使用监测调查数据,对过去两年内尝试戒烟的现吸烟者和既往吸烟者(N = 26,094)进行二次分析。回归模型检验了不同SSM覆盖范围(即无覆盖、部分覆盖或全面覆盖)的省份在SSM使用和戒烟成功率方面的差异。

结果

与部分覆盖(比值比[OR]=1.39,95%置信区间[CI]=1.22, 1.59)或无覆盖(OR = 1.43,95% CI = 1.21, 1.68)的司法管辖区相比,吸烟者在全面覆盖SSM的司法管辖区更有可能使用尼古丁替代疗法(NRT)。在部分覆盖(与无覆盖相比)的省份,使用处方药的可能性更大(OR = 1.27,95% CI = 1.01, 1.59)。总体而言,尝试戒烟的吸烟者在全面覆盖的司法管辖区比部分覆盖(OR = 1.20,95% CI = 1.12, 1.28)或无覆盖(OR = 1.23,95% CI = 1.00, 1.50)的司法管辖区更有可能保持戒烟状态。观察到覆盖范围与每日吸烟量之间存在交互作用,这表明全面覆盖对重度吸烟者的潜在影响可能更大。

结论

全面补贴政策与NRT使用和戒烟成功率的适度提高相关,但似乎并未影响处方SSM的使用。

相似文献

1
Stop-Smoking Medication Use, Subsidization Policies, and Cessation in Canada.加拿大的戒烟药物使用、补贴政策与戒烟情况
Am J Prev Med. 2015 Aug;49(2):188-98. doi: 10.1016/j.amepre.2015.03.001. Epub 2015 May 29.
2
An increase in primary care prescriptions of stop-smoking medication as a result of health insurance coverage in the Netherlands: population based study.由于荷兰的医疗保险覆盖范围,初级保健处方中戒烟药物的增加:基于人群的研究。
Addiction. 2013 Dec;108(12):2183-92. doi: 10.1111/add.12289. Epub 2013 Aug 14.
3
Effectiveness of a national reimbursement policy and accompanying media attention on use of cessation treatment and on smoking cessation: a real-world study in the Netherlands.一项国家报销政策及相关媒体关注对戒烟治疗使用情况和戒烟效果的影响:荷兰的一项真实世界研究
Tob Control. 2015 Sep;24(5):455-61. doi: 10.1136/tobaccocontrol-2013-051430. Epub 2014 May 18.
4
Factors associated with the use of aids to cessation in English smokers.与英国烟民使用戒烟辅助用具相关的因素。
Addiction. 2009 Aug;104(8):1403-10. doi: 10.1111/j.1360-0443.2009.02639.x. Epub 2009 Jun 22.
5
What cigarette price is required for smokers to attempt to quit smoking? Findings from the ITC Korea Waves 2 and 3 Survey.吸烟者尝试戒烟需要什么样的香烟价格?国际烟草控制(ITC)韩国第2轮和第3轮调查结果
Tob Control. 2015 Jul;24 Suppl 3:iii48-iii55. doi: 10.1136/tobaccocontrol-2015-052232. Epub 2015 Jun 22.
6
Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.希腊伐伦克林与安非他酮、尼古丁替代疗法和非药物戒烟的成本效益比较。
Clin Ther. 2012 Aug;34(8):1803-14. doi: 10.1016/j.clinthera.2012.07.002. Epub 2012 Jul 20.
7
Cessation Behaviors and Treatment Use Among U.S. Smokers by Insurance Status, 2000-2015.2000-2015 年美国吸烟者按保险状况的戒烟行为和治疗使用情况。
Am J Prev Med. 2019 Oct;57(4):478-486. doi: 10.1016/j.amepre.2019.06.010. Epub 2019 Aug 22.
8
Student and school characteristics associated with use of nicotine replacement therapy: a multilevel analysis among Canadian youth.学生和学校特征与尼古丁替代疗法的使用相关:加拿大青少年的多层次分析。
Addict Behav. 2012 Jul;37(7):811-6. doi: 10.1016/j.addbeh.2012.03.012. Epub 2012 Mar 17.
9
Mental health and smoking cessation-a population survey in England.心理健康与戒烟——英格兰的一项人群调查。
BMC Med. 2020 Jun 25;18(1):161. doi: 10.1186/s12916-020-01617-7.
10
Reach and effectiveness of mailed nicotine replacement therapy for smokers: 6-month outcomes in a naturalistic exploratory study.邮寄尼古丁替代疗法对吸烟者的效果和影响:一项自然探索性研究的 6 个月结果。
Tob Control. 2013 May;22(3):e4. doi: 10.1136/tobaccocontrol-2011-050303. Epub 2012 Apr 11.

引用本文的文献

1
Individual and Conjoint Factors Associated With Beliefs About the Harmfulness of Nicotine Replacement Therapies Relative to Combustible Cigarettes Among People Who Smoke: Findings From the 2020 ITC Four Country Smoking and Vaping Survey.与吸烟人群相比,认为尼古丁替代疗法相对于可燃香烟危害性更小的个体和联合因素:2020 年 ITC 四国吸烟与蒸气调查结果。
Nicotine Tob Res. 2023 Aug 19;25(9):1594-1602. doi: 10.1093/ntr/ntad075.
2
Genetic predisposition to smoking in relation to the risk of frailty in ageing.遗传易感性与吸烟衰老相关脆弱的风险。
Sci Rep. 2023 Feb 10;13(1):2405. doi: 10.1038/s41598-023-28780-0.
3
If You Pay, Will They Come? Evaluating the Impact of Subsidies on Cessation Outcomes in the Walk or Run to Quit Program.
如果你付费,他们会来吗?评估补贴对“步行或跑步戒烟计划”戒烟成果的影响。
J Smok Cessat. 2022 Sep 9;2022:7929060. doi: 10.1155/2022/7929060. eCollection 2022.
4
Variability in patient sociodemographics, clinical characteristics, and healthcare service utilization among 107,302 treatment seeking smokers in Ontario: A cross-sectional comparison.在安大略省寻求治疗的 107302 名吸烟者中,患者社会人口统计学、临床特征和医疗服务利用的变异性:横断面比较。
PLoS One. 2020 Jul 10;15(7):e0235709. doi: 10.1371/journal.pone.0235709. eCollection 2020.
5
Does free nicotine replacement improve smoking cessation rates in cancer patients?免费尼古丁替代疗法能否提高癌症患者的戒烟率?
Curr Oncol. 2020 Feb;27(1):14-18. doi: 10.3747/co.27.5267. Epub 2020 Feb 1.
6
How does reimbursement status affect smoking cessation interventions? A real-life experience from the Eastern Black Sea region of Turkey.报销状况如何影响戒烟干预措施?来自土耳其黑海东部地区的实际经验。
Tob Induc Dis. 2019 Jan 22;17:05. doi: 10.18332/tid/100412. eCollection 2019.
7
Use of smoking cessation products: A survey of patients in community pharmacies.戒烟产品的使用:社区药房患者调查。
Can Pharm J (Ott). 2017 Aug 2;150(5):326-333. doi: 10.1177/1715163517723035. eCollection 2017 Sep-Oct.